[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578010":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":7,"locations":8,"responsibleParty":32,"collaborators":34,"id":39,"slug":7,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":7,"maxAge":47,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":11,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","OTHER",null,[9],{"facility":10,"status":11,"city":12,"state":7,"zip":13,"country":14,"countryCode":15,"cosmosGeoPoint":16,"geoPoint":21,"contacts":22},"Fondazione IRCCS Istituto Neurologico Carlo Besta","RECRUITING","Milan","20133","Italy","IT",{"type":17,"coordinates":18},"Point",[19,20],12.59836,42.78235,{"lat":20,"lon":19},[23,28,30],{"name":24,"role":25,"phone":26,"phoneExt":7,"email":27},"Stefano D'Arrigo, MD","CONTACT","02.2394.2210","stefano.darrigo@istituto-besta.it",{"name":29,"role":25,"phone":7,"phoneExt":7,"email":7},"Claudia Ciaccio, MD",{"name":29,"role":31,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[35,37],{"name":36,"class":6},"Azienda Ospedaliera Sant'Anna",{"name":38,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","100578010",false,"NCT06805734","Natural History With Focus on Oncological Risk Evaluation in Pediatric Patients With PTEN Pathogenic Variants","Natural History With Focus on Oncological Risk Evaluation in Pediatric Patients With PTEN Pathogenic Variants - Observational Study","PTEN_Ped","Inclusion Criteria:\n\n* PTEN pathogenic variants (class 4\u002F5 SNV, gene deletion, intragenic duplication\u002Fdeletion)\n* Pediatric patients (\\\u003C18 years old) and their affected relatives, male\u002Ffemale, all ethnicities\n* The legal representative must agree to follow the screening protocol\n* Informed consent signed by the legal representative\n\nExclusion Criteria:\n\n* Refuse to undergo the exams of the protocol assessment at the diagnosis\n* PTEN non-pathogenic variants (VOUS or benign\u002Flikely benign vatiants)\n* No signed informed consent","ALL","17 Years",{"count":49,"type":50},50,"ESTIMATED","OBSERVATIONAL","This is an observational study in pediatric patientis carryng PTEN pathogenic variants aimed to define oncological risk in children and provide a deeper insight of the clinical course, establishing an updated follow-up protocol.",[54],"PTEN Hamartoma Syndrome",[56,57],"PTEN","PTHS","2026-02-10",{"date":60,"type":61},"2026-02-12","ACTUAL",{"date":63,"type":61},"2024-08-01",{"date":65,"type":50},"2029-07",{"name":5,"class":6},1]